Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

980
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
980
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.7K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.7K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.1K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.0K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mindfulness-based cognitive therapy for psoriasis.

Journal of the American Academy of Dermatology·2026
Same author

Development and validation of the Oxford Attitudes to Artificial Intelligence in Medicine Scale.

JAAD international·2026
Same author

Quality-of-life impact rather than overall severity may help guide therapeutic options in psoriasis.

Journal of the American Academy of Dermatology·2026
Same author

Stress and skin disease.

Journal of the American Academy of Dermatology·2026
Same author

In vivo skin fluorescence imaging for dysplastic nevi and melanoma.

Journal of the American Academy of Dermatology·2026
Same author

Interpreting the global burden of disease 2023 dermatology estimates: Best practices, caveats, and limitations for researchers and clinicians.

JAAD international·2026
Same journal

Hypoactive Sexual Desire Disorder in Menopausal Women: Dermatologic Implications of Antiandrogen and Testosterone Therapy.

Journal of the American Academy of Dermatology·2026
Same journal

Incise parallel, section perpendicular to the dermatoglyphs for diagnosis of acral melanocytic lesions-A comment on Thakker et al.

Journal of the American Academy of Dermatology·2026
Same journal

Response to Xue et al, "Defining super-responders is not the same as predicting rituximab response in pemphigus".

Journal of the American Academy of Dermatology·2026
Same journal

Comment on Nie et al. (2026) 'Suicidality Reports in Acne Patients Treated with Isotretinoin and Concomitant Antidepressants: A Descriptive Analysis of FDA Adverse Event Reporting System Data'.

Journal of the American Academy of Dermatology·2026
Same journal

Defining super-responders is not the same as predicting rituximab response in pemphigus.

Journal of the American Academy of Dermatology·2026
Same journal

Eosinophilic fasciitis induced by checkpoint inhibitors: a retrospective multicenter case-series, comparison with eosinophilic fasciitis unrelated to checkpoint inhibition and literature review.

Journal of the American Academy of Dermatology·2026
See all related articles

Related Experiment Video

Updated: Feb 6, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

941

GLP-1 receptor agonists as potential adjunctive therapeutic options for hidradenitis suppurativa and psoriasis

Jonathan Kantor1

  • 1Department of Engineering Science, University of Oxford, Oxford, UK, Center for Global Health and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania and Florida Center for Dermatology, St Augustine, Florida.

Journal of the American Academy of Dermatology
|February 4, 2026
PubMed
Summary

No abstract available in PubMed .

Keywords:
GLP-1-RAepidemiologyglucagon-like peptide-1 agonisthidradenitismetabolic dysfunctionobesitypsoriasis

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K

Related Experiment Videos

Last Updated: Feb 6, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

941
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.8K